A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...
Zacks.com on MSN2d
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.
After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...
Centessa Pharmaceuticals plc shifts focus to ORX750 for sleep disorders after discontinuing SerpinPC. Click here to find out ...
Zacks Investment Research on MSN2d
AXSM Stock Down on Top-Line Data From Depression Study on SolriamfetolAxsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...
Axsome Therapeutics said on Tuesday it will narrow the focus of a late-stage study of its depression drug after an initial ...
MedPage Today on MSN2d
AI Chatbot Helps Mental Health; Neuroplastogen for PTSD: Magic Mushroom DispensariesAxsome Therapeutics said it's dopamine and norepinephrine reuptake inhibitor solriamfetol (Sunosi), approved for excessive daytime sleepiness, failed to reduce symptoms of major depressive disorder in ...
Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes ...
Investor's Business Daily on MSN7h
Stock Market In Vertical Sell-Off On Trump Tariffs; Tesla Deliveries Fall – Weekly ReviewThe major indexes suffered their worst weekly losses in years as the latest Trump tariffs were far higher than expected.
Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback